Programme
Accelerate Alumni (Cohort 4)
Founded in
2014
Total funds raised
£66.4 million
Employees
51-100
Industry
Healthcare, pharma, biotech
At the centre of Healx’s approach is it’s next-generation AI platform built to find novel connections between drugs and diseases. Healx combine these predictions with in-house expertise to accelerate new treatments through their pipeline to clinical trials and on to patients.
Rare diseases are often not well studied and there is a limited understanding of many of the aspects necessary to support a drug discovery programme. Healx’s AI platform overcomes these challenges by analysing millions of drug and disease data points to find novel connections that could be turned into new treatment opportunities. By applying frontier technologies across the discovery and development pipeline, Healx can run multiple stages in parallel and at scale.